<DOC>
	<DOCNO>NCT02493452</DOCNO>
	<brief_summary>This study patient IBS-C randomize , double-blind , placebo-controlled , parallel-group clinical trial 12 week study drug therapy .</brief_summary>
	<brief_title>Second Plecanatide Study In Irritable Bowel Syndrome With Constipation ( IBS-C )</brief_title>
	<detailed_description>This study patient IBS-C randomize , double-blind , placebo-controlled , parallel-group clinical trial 12 week study drug therapy . Screening/Baseline : Patients undergo 28-day Screening/Baseline period allow necessary diagnostic procedure , allow require washout medication determine study eligibility . If otherwise eligible base screening criterion , patient undergo 2-week baseline assessment use electronic diary record daily assessment bowel movement ( BMs ) , stool consistency ( Bristol Stool Form Scale-BSFS ) , abdominal pain IBS-related symptom . Data two-week electronic diary assessment prior randomization visit use confirm IBS-C study eligibility well define patient 's baseline change determine . Treatment : Patients meet entry criterion randomize ( 1:1:1 ) one three blind treatment group Day 1 Treatment period . Patients take oral dose study drug OD 12 week continue daily electronic diary ( BMs , rescue medication use , abdominal pain , symptom ) . During treatment week 4 , 8 , 12 , patient return clinic undergo safety efficacy assessment . Post-Treatment : For 2 week complete dosing , patient continue complete daily electronic diary . Patients return clinical site final follow-up visit Week 14 follow randomization . The planned duration participation study least 116 day sign informed consent post-treatment approximately 135 day visit window consider .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>• Adult patient age 18 85 year ( inclusive ) diagnosis IBS base ROME III diagnostic criterion meet criterion diagnosis constipation predominant subtype IBSC Refusal inability sign inform consent trial Refusal inability complete daily Episodic ( realtime ) BM / RM call , End Day daily Calls , and/or complete electronic questionnaire BMI ≥ 40 &lt; 18 Women child bear potential refuse use acceptable method birth control duration trial Women pregnant lactate Diagnosis IBSD IBSM Organic obstructive disease small large intestine Use laxatives studysupplied rescue medication ( Dulcolax® , bisacodyl ) Use prohibit concomitant medication within time frame prior screen outline study protocol medication Unstable medical illness Bilirubin &gt; 3X ULN absence conjugation defect Any laboratory value &gt; 3X ULN unless discuss approve study Medical Monitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>